MH

Maykin Ho

Board Director at Agios, BioMarin, Fibrogen, Neumora and Parexel. Venture Partner of Qiming. Retired partner of Goldman Sachs.

New York, New York

Investor
VC

Invests in

Locations:

Shanghai
China

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Biotechnology Industry
Healthcare Industry
Investment Banking
Investment Research
China Business Development
IPO
Business Strategy
Business Development
Venture Capital
Asset Management
Company Valuation
Financial Analysis
Hedge Funds
Greater China
Alternative Investments
Pharmaceutical Industry
Emerging Markets
Life Sciences
Investor Relations
Stock Picking

Education

Lists including Maykin

AM
AR
AG
AH

Based in NYC

2599 people

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Work Experience

N
Neumora

2021

  • Board Member

    2021

BP
BioMarin Pharmaceutical Inc.

2021

  • Board Member

    2021

FI
FibroGen, Inc.

2018

  • Board Member

    2018

P
PAREXEL

2015

  • Board Member

    2015

AP
Agios Pharmaceuticals

2015

  • Board Member

    2015

Qiming Venture Partners 启明创投

2015

  • Venture Partner

    2015

Viridian Global LLC

2015

  • Partner

    2015

GI
GRAIL, Inc.

2019 - 2020

  • Board Member

    2019 - 2020

GS
Goldman Sachs

1992 - 2015

  • Advisory Director, Healthcare Investment Banking

    2010 - 2015

    Healthcare Investment Banking in China and US

  • Partner, Senior Biotechnology Analyst

    1992 - 2010

    Partner and Co-head of Healthcare Research, Global Investment Research (2002-2010) Head of Biotechnology Investment Research (1992-2010)

DuPont Merck Pharmaceutical Company

1991 - 1992

  • Director, Strategic Planning and Licensing

    1991 - 1992